From Simple Liquids to Surgical Instruments: On the History of Ophthalmo-Viscosurgical Devices (OVD) by Scholtz, Sibylle K. & Auffarth, Gerd U.
ARCHIW UM HISTORII I FILOZOFII MEDYCYNY 2012, 75, 16-25
SIB YLLE  K. SCH O LTZ, G ERD  U. A U FFA RTH
From Simple Liquids to Surgical Instruments: 
On the History of Ophthalmo-Viscosurgical Devices (OVD)
Od prostych płynów do narzędzi chirurgicznych: 
historia preparatów wiskoelastycznych (OVD)
International Vision Correction Research Centre (IVCRC), Dept. o f Ophthalmology, University o f Heidelberg, Germany
Summary
N ow adays, O VDs are regarded as standard tools in 
ophthalm ic surgery. Their discovery and development 
started about 70 years ago, in 1934, with isolating hy­
aluronic acid as the substance o f  the vitreous body o f 
the hum an eye. Sodium  Hyaluronate was the first sub­
stance used as an OVD and is now the m ost w idely 
used material for OVDs used in ophthalm ic surgery. 
It has becom e “the gold standard” to which all other 
viscoelastics are compared. Since the introduction o f 
viscoelastic substances in the 1970s the properties o f 
these agents have improved the quality o f anterior seg­
ment surgery. Therefore OVDs had — and still have 
— a great im pact on the success o f ophthalm ic sur­
gery — especially o f cataract surgery and intraocular 
lens implantation. In vivo studies have proven that the 
m olecular and chem ical structure o f hyaluronic acid 
is ideal. Interactions between molecules and receptor 
tissues and inflam m atory and im m unogenic reactions 
have also been studied extensively. This article shows 
the historical development o f the different substances 
used nowadays and their properties.
Keywords: history, Ophthalmo-Viscosurgical Devices, 
OVD, viscoelastic substances, hyaluronic acid
Streszczenie
Preparaty wiskoelastyczne są obecnie uważane za standar­
dowe narzędzia w  operacjach okulistycznych. Ich odkrycie 
i rozwój zostały poprzedzone wyizolowaniem w  1934 roku 
kwasu hialuronowego z ciała szklistego ludzkiego oka. 
Hialuronian sodu był pierwszą substancją używaną w  cha­
rakterze preparatu wiskoelastycznego i obecnie jest naj­
powszechniej używanym materiałem wiskoelastycznym 
w  operacjach okulistycznych, stając się wzorcem, do któ­
rego porównywane są inne substancje wiskoelastyczne. 
Od momentu zastosowania w  latach siedemdziesiątych 
materiały te, dzięki swoim właściwościom, przyczyniły się 
do poprawy wyników operacyjnych w  przednim odcinku 
oka. Preparaty wiskoelastyczne miały i nadal mają wielki 
wpływ na powodzenie zabiegów okulistycznych, a zwłasz­
cza operacji usunięcia zaćm y i wszczepienia sztucznej 
soczewki wewnątrzgałkowej. Badania in vivo wykazały, że 
struktura molekularna i chemiczna kwasu hialuronowego 
jest idealna. Badane były również wzajemne oddziaływa­
nia między kwasem hialuronowym a tkankami oka oraz 
reakcje zapalne i immunologiczne. Ten artykuł przedsta­
wia historię rozwoju obecnie stosowanych materiałów 
wiskoelastycznych oraz ich właściwości.
Słowa kluczowe: historia, preparaty wiskoelastyczne, 
OVD, substancje wiskoelastyczne, kwas hialuronowy
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Introduction
Nowadays, O phthalm o-viscosurgical devices (OVD) 
are regarded as standard tools in ophthalmic surgery. 
Their discovery and development started approximately 
70 years ago, in 1934, with isolating hyaluronic acid as 
the substance of the vitreous body of the human eye. 
This article shows the historical development o f today’s 
different used substances and their properties. Today, 
Hyaluronic acid is more and more used in eye drops and 
contact lens rewetters due to its high wetting and water 
binding properties. Therefore, this article will review the 
historical development and usage o f this com pound in 
cataract surgery.
Material and Methods
The outcome of this article is based on an intensive re­
search o f current and historic literature on the topic in 
discussion. This article evaluates 65 scientific articles on 
the topics hyaluronic acid and ophthalmic viscosurgical 
devices.
Results
OVDs (Ophthalmic Visco-surgical Devices) [1] — for­
merly called viscoelastics or viscoelastic substances - are 
a class o f non-active clear gel-like chemical compounds 
with viscous and elastic properties [2]. The specific phys­
ical properties make them useful e.g. for ophthalm ic 
surgery, m ainly cataract surgery [3]. (Here) they create 
and maintain the anterior chamber depth and visibility, 
protect the corneal endothelium and other intraocular 
tissues during surgery. OVDs minimize interaction be­
tween tissues and instruments during surgery and ensure 
therefore high tissue integrity [4, 5].
OVDs are essential in ophthalmic surgery today. Their 
use became increasingly popular for cataract surgery, 
glaucoma surgery, cornea surgery, trauma surgery, and 
vitreoretinal surgery [6, 7].
Since the introduction o f viscoelastic substances in the 
1970s the properties o f these agents have improved the 
quality o f anterior segment surgery.
OVDs are clear viscous fluids used in ophthalmic surgery, 
packed in a syringe, and are delivered through a cannula 
into the eye. Based on their properties, OVDs can be 
divided into two groups [8]:
— Cohesive agents show high viscosity, adhere to 
themselves, and act like a gel. The molecules are long 
chains, have a high m olecular weight, and show high 
pseudoplasticity and surface tension.
— Dispersive agents show low viscosity, the m ol­
ecules behave separately, they build up a solution. They
show low pseudoplasticity and surface tension with short 
chains and low molecular weight.
Historical background
In 1934, M eyer and Palmer were able to isolate hyaluronic 
acid, a polysaccharide from the vitreous cortex [9, 10]. 
Hyaluronic acid was also purified from umbilical cord 
and rooster combs by Endre Balazs [11]. In 1958, he has 
been the first who suggested the use o f hyaluronic acid 
as a possible vitreous substitute in the perform ance o f 
complicated retinal detachment surgery [12]. In 1972, 
Balazs perform ed the first intravitreous injection o f hy­
aluronic acid [13].
M iller and Stegman suggested the use o f hyaluronic 
acid during the implantation o f intraocular lenses [14]. 
Sodium  hyaluronate was used in 1977 by M iller to per­
form experimental IOL (Intra-Ocular Lens) implantation 
in rabbit eyes [15]. In the same year, Fechner used a 1% 
solution o f methylcellulose to maintain the volume o f the 
anterior chamber [16]. Beside o f Fechner different other 
surgeons described methylcellulose as an inexpensive 
alternative to hyaluronic acid used as an OVD [17, 18].
In 1979, during a symposium on ocular surgery, Balazs 
presented the patent o f viscoelastic material with high 
molecular weight (“HMW  VE NIF-NAH A”) [19] consist­
ing o f purified hyaluronic acid, which was used in an IOL 
implantation procedure. At the same video symposium, 
a new terminology “Viscosurgery” was born, also coined 
by Balazs. In the same year Balazs sold his US-patent 
to the com pany Pharm acia  which developed the first
viscoelastic product (Healon®), also in 1979. H ealon® is 
today still available distributed by AMO (Abbott M edi­
cal Optics).
1976 hyaluronic acid gained the U S IND (Investiga­
tional New Drug) application. M iller and Stegmann sub­
mitted 1977 IND for IOL use, Pape IND for cataracts, and 
glaucoma and Pollach IND for corneal transplants. In 
1 9 7 9 , Healon* got the 510k permission to market granted. 
At the AAO (Am erican Academ y o f Ophthalmology) 
congress in November 1979, H ealon* was first presented 
at a scientific exhibition. The product launch took place 
at the ASCRS (Am erican Society o f Cataract and Refrac­
tive Surgery) congress in April 1980. The approval o f the 
FDA followed in January 1983.
Since the introduction o f H ealon* (sodium  hy- 
aluronate, 1%), ophthalm ic viscosurgical devices have 
become essential tools, particularly in anterior segment 
surgery. The use o f OVDs creates and maintains anterior 
chamber depth and visibility. It protects the sensitive en­
dothelium and other intraocular tissues, and minimizes 
interaction between tissues and instruments during sur­
gery [20-22]. Space and surface tactical aspects o f OVD
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application have first been shown by Eisner [23], tech­
niques like visco-blockade, — tamponade or — spatula 
have been invented by him [24].
Therefore OVDs had — and still have — a great im ­
pact on the success o f cataract surgery and intraocular 
lens implantation [25-30].
From 1995 to 2000 ISO developed an International 
Standard for the safety, perform ance and approval re­
quirements for viscoelastics under a new designation o f 
Ophthalmic Viscosurgical Devices (OVDs) [31].
A dd itionally , the developm ent o f new  surgical 
techniques in cataract extraction  procedures such 
as phacoem ulsification, invented by Charles Kelm an 
1967, and foldable IOL implantation (since 1988) was 
accom panied by the developm ent o f  new m odalities 
o f viscoelastics.
V iscoelastics have a wide range o f features with 
rheologic-related properties such as viscosity, elasticity, 
pseudo-plasticity, cohesiveness, etc. [32-34]. Although 
the properties exist independently, they act synergisti- 
cally. The same viscoelastic can be used as a different tool 
according to specific needs, such as separating or joining 
tissues, maintaining space, or protecting surfaces (i.e. 
corneal endothelium, lens capsule or anterior hyaloid) 
from mechanical trauma or fluids infusion.
Viscosurgery procedures are not limited to cataract 
surgery. They are now routinely used in anti-glaucoma 
filtering surgery, combined surgical interventions, ker­
atoplasty, and anterior vitrectomy [35, 36].
In corneal surgery, Alpar observed reduced endothe­
lial cell loss in various keratoplasty procedures performed 
with Healon® in 1984 [37]. Findings o f reduced complica­
tion rate with OVDs have been confirmed by other stud­
ies. Beside protection, an OVD depot (dome) supports 
and stabilizes the donor cornea (cushion) after removal 
o f recipient cornea, and facilitates positioning. Healon® 5, 
a new, high concentration viscoadaptive OVD becomes 
more and more popular for this procedure.
In glaucoma surgery, anterior chamber collapse dur­
ing trabeculectomy is a common complication and plays 
an important role in cataract formation following glau­
coma surgery. Also, less post-op hyphemata is observed. 
OVDs in other glaucoma procedures are used to improve 
visibility, avoid bleeding (tamponade), or open chamber 
angles.
In trauma surgery OVDs are used in treating per­
forating bulbar injuries (stabilizing anterior chamber, 
separating o f tissue). They provide a better overview 
at operation site by im proving the visibility o f the in­
jured anatomic structure. Furthermore, OVDs reduce 
intraocular bleeding, and foreign bodies can be moved/ 
removed very safely.
The usage o f OVDs in vitreoretinal surgery is related 
to the early history o f OVDs. With new agents for the use 
in the posterior segment — like gases, perfluorocarbons, 
or silicone oil — as endotamponade, the importance o f 
OVDs have decreased.
Substances used as ophthalmo-viscosurgical devices
Sodium  Hyaluronate was the first substance used as 
an OVD and is now the most widely used material for 
OVDs used in ophthalmic surgery. It has become “the 
gold standard” to which all other viscoelastics are com ­
pared [38].
H yaluron ic acid (Sod ium  H yaluronate, N aH a) 
[39-45] is a linear polysaccharide molecule o f sodium 
glycuronate and N-acetyl glucosamine. The molecular 
weight may range from 100,000 to 7 million Daltons; the 
molecule consists o f nearly 10,000 disaccharide units. 
Hyaluronic acid which is used in OVDs is prim arily ex­
tracted from rooster combs. It is a natural biological sub­
stance in all vertebrates, humans, and also some bacteria. 
High concentrations are found in hum an connective 
tissue and in the eye (vitreous, cortex, and trabecular 
meshwork), low concentrations in aqueous hum or and 
corneal endothelium. Hyaluronic acid seems to be re­
cently the most widely used OVD worldwide.
o J o
f i g . 1. Chemical structure o f hyaluronic acid
Chondroitin Sulfate (CS) [46], [36] is like hyaluronic 
acid a biological substance in the extracellular matrix 
m ainly in solid tissue parts like cartilage or corneal stro­
ma. For use the as an OVD the polysaccharide is mainly 
extracted from shark-fin cartilage. M olecular weight is 
about 20,000 D, the chain length 50 nm which gives the 
molecule a lower viscosity and negative charge.
f i g . 2. Chemical structure o f Chondroitin sulfate
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Methylcellulose (MC) [47-49] is widely distributed 
in cotton and wood but not in humans or animals. It 
is a disaccharide (glucose units) with side chains to 
make the molecule more hydrophilic. In ophthalmol­
ogy methylcellulose is used as a lubricant because o f its 
good wetting and coating capacity. From  an im m uno­
logical aspect it is important that this substance does 
not occur naturally in the human body, and therefore 
shows a significant inflam m atory potential. It will not 
be metabolized completely.
f i g . 3. Chemical structure o f methylcellulose
Polyacrylam ide is a synthetic polym er with a high 
molecular weight derived from acrylamide which con­
sists o f long carbon chains. The product was withdrawn 
from the market in 1991 after observing intraocular pres­
sure elevation treated with this material. Poyacrylamid 
is today only o f historical interest [7].
Collagen as a viscoelastic material consisting o f Type 
IV  collagen can be extracted from human tissue as well 
as from  animal tissue (pigs). Up to now, there is less 
information about the ideal origin o f this substance for 
using it as OVD [7].
Further substances as a basis for OVD were suggested 
but attained however no clinical relevance [50].
Rheological and physico-chemical properties of 
substances used as ophthalmo-viscoelastic devices
The description and characterization o f different v is­
coelastic substances is a prerequisite for understanding 
their specific properties and from this their intended use. 
A  profile o f requirements for daily surgical practice can 
be established which indirectly presupposes the exis­
tence o f certain physico-chemical characteristics. These 
substances must be easily and quickly injected, protect 
the corneal endothelium, and have the capacity to create 
and maintain intraocular space or compartments. It is 
important that optimal sight, i.e. optimal transparency 
o f the material, is established during surgery. During the 
last stage o f surgery the substance should be both, easily 
and quickly removable, or be naturally digested in the 
eye. In either case there should be no rise in intraocular 
pressure during the early postoperative phase.
Some o f these functions are contradictory: Water- 
based solutions are most easily injectable since they offer 
almost no resistance. Viscous or viscoelastic substances 
are slower to flow through a cannula; m oreover this 
speed is dependent on cannula diameter and pressure 
on the plunger.
Additionally, corneal endothelial protection presup­
poses a certain stickiness and adhesion o f the viscous 
substance to the tissue, which makes the removal o f the 
substance more difficult. A  strong space-m aintaining 
capacity can also cause problems during the removal 
o f the substance. The characteristics mentioned before 
can be described by the properties o f the specific visco- 
surgical device, like: viscosity, elasticity, viscoelasticity, 
pseudoplasticity, cohesion, and its contact angle.
Viscosity is a measure o f fluency resistance o f a fluid, 
indicating how viscous a substance is. Viscosity is de­
pendent on several factors including molecular weight, 
molecule size, concentration, and temperature. Viscosity 
can be measured physically by placing the substance be­
tween two parallel plates and then moving these against 
each other. The “ frictional resistance” o f a viscoelastic 
can thereby be quantified. During this experiment the 
following terms are also interesting for day to day clinical 
use. The shear rate represents the speed with which the 
plates are shifted against each other (Unit rad/s = radiant 
per second or hertz =Hz, 1/second). The force needed to 
shift the plates per surface unit is called shear force (unit 
dynes/cm2). The so-called velocity gradient refers to the 
ratio between the relative speed o f shifting the disk and 
thickness o f the substance between the disks. This term 
is important since the quotient o f shear force and veloc­
ity gradient is the measure o f dynamic viscosity (unit 
N  x  sec x  m-2 = Poise, P for Poiseuille). The quotient o f 
dynam ic viscosity and fluid density is called kinematic 
viscosity (unit Stokes, St).
Zero Shear Viscosity refers to viscosity at rest, i.e. at 
a shear rate o f zero. This term is frequently seen as par­
ticularly characteristic o f viscoelastics. It is interesting to 
note that there is practically no way in which this value 
can be measured and is therefore always theoretically cal­
culated through extrapolating. This value should be sur­
veyed censoriously and not used as an exclusive measure 
to judge a viscoelastic. A  practical value o f this measure 
exists nonetheless, for example good space-maintaining 
capacity can be achieved with a high zero shear viscosity, 
meaning that a deepening o f the anterior chamber and 
the creation o f space is highly successful. Comparatively, 
a viscoelastic with low zero shear viscosity, as in cases of 
high vitreous pressure can flow out o f the incision.
The next term to be considered is o f the term elastic­
ity. In the physical sense, elasticity describes the ability to
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offer resistance to a force and the ability o f a substance to 
return to its original form following the removal o f the 
force. Elasticity is also dependent on molecular weight 
and concentration, and is influenced by the frequency o f 
the influencing force as well. Hyaluronic acid prepara­
tions tend to behave like viscous fluids in a low frequency 
range (0,1 to 10 Hertz) and more like elastic bodies at 
higher frequencies.
The term viscoelastic gives a name to an entire sub­
stance group. It is a term that describes substances which 
can behave both, viscous and elastic. Viscoelastic sub­
stances offer low resistance towards deform ing forces 
and do not have the ability to im m ediately return to 
their original form, and indeed will never be able to fully 
reach their original form. This refers to relative form 
stability.
As a rule, all viscoelastics consist o f a molecular net­
work with varying concentrations. Most viscoelastics be­
have viscous if  a force with low speed and low frequency 
act on them. The added energy is converted to heat, since 
the molecular chains shift against each other. At higher 
frequencies or fast energy impact, the viscoelastic acts 
like a shock absorbing gel cushion. Energy is elastically 
stored and dispensed with relative form stability. W hich 
o f the characteristic above prevails is dependent upon the 
type o f force effect, and in particular the concentration 
and temperature. The above described characteristic o f 
viscoelasticity is also referred to as pseudoelasticity.
Natrium hyaluronates show the highest pseudoelastic­
ity. For practical purposes this means that they have high 
viscosity (zero shear viscosity) at rest. Therefore, they 
have good space-maintaining capabilities. Less viscous 
chondroitinsulfate-natrium hyaluronate combinations 
such as Viscoat (Alcon) have better coating capabilities. 
Low pseudoelasticity o f chondroitinsulfate leads to the 
substance adhering longer to the corneal endothelium 
and therefore not being rinsed out o f the eye as quickly as 
hyaluronic acid preparations which have the tendency to 
quickly rinse out o f the eye “en bloc”. This is a particular 
advantage during phacoemulsification where relatively 
high volumes o f fluid are used.
A  further term that describes the properties o f vis­
coelastics is coating ability. This refers to the degree o f 
adhesion o f a viscoelastic on a surface. It is ascertained 
through the contact angle o f the substance with the 
surface and surface tension. W hen a substance forms 
a strong curvature change on the surface, a large contact 
angle is formed. This points to little adhesion. For clarifi­
cation, an extreme case o f this would be a drop o f water 
that repels off the surface o f a Gore-Tex jacket.
Two further terms that are often associated with the 
characterization o f viscoelastics are cohesion and disper­
sion. Cohesion refers to extent to which a viscoelastic 
substance is held together through intermolecular bind­
ings and molecular chains. Higher molecular viscoelas­
tics (e.g. Healon G V  (AMO)) with long molecular chains 
are cohesive. A  substance like this can escape or be rinsed 
out o f the eyes “en bloc” during aspiration. Dispersive 
viscoelastics (e.g. Viscoat (Alcon)) are generally low m o­
lecular with shorter and less tightly weaved molecular 
chains. They do not leave the eyes “en bloc” but rather 
show a tendency to become glued to the structures and 
are therefore often difficult to aspirate. A  description o f 
cohesion and dispersion o f different viscoelastics was put 
forth in an experimental study through means o f the Co- 
hesion-Dispersion-Index (CDI) [70]. The CDI represents 
the quotient o f the share o f the aspirated viscoelastic in 
percentage, measured in time and the respective aspira­
tion setting. The faster and the more viscoelastic could 
(or can??) be removed, the higher the CDI. This would 
be e.g. 72,3 for Healon G V (AMO ) , 46 for Provisc (Alcon), 
21,4 for Healon (AMO) and 3,4 for Viscoat (Alcon).
Most important is still the use o f viscosurgical devices 
in cataract surgery. D uring the manipulation o f capsu- 
lorhexis it is also important that the anterior chamber 
remains stable, once again making high viscosity impor­
tant. While good pseudoplasticity is most important in 
nucleus expression, low cohesion and high dispersion 
are essential during phacoemulsification, preventing the 
viscoelastic from being rinsed out o f the eye. This also ap­
plies to the steps o f irrigation/aspiration during cortical 
cleanups. Opening and stabilizing the capsular bag for 
IOL-implantation requires a good space-maintaining ca­
pacity and therefore high viscosity and pseudoplasticity. 
Good cohesion, meanwhile, is helpful for a fast and com­
plete removal o f the substance [1, 4, 6, 7, 10, 34-36].
Viscoelastic devices used in ophthalmology
The physico-chem ical properties o f viscoelastics de­
scribed above allow them to be used in a variety o f ways 
and carry out a number o f different functions. Particu­
larly in cataract surgery there is a demand for the “ ideal” 
viscoelastic which requires partly contradictory charac­
teristics. For clinical purposes it is therefore an advantage 
to have in-depth knowledge o f the individual properties 
in order to use specific substances or a combination of 
substances depending on the circumstances.
An integral function o f viscoelastics is to maintain the 
anterior chamber not only during cataract surgery, but 
also during other corneal surgical procedures, glaucoma 
surgeries, trauma, and revision-surgeries in the anterior 
eye segment. The viscosity and elasticity o f a substance 
determ ine o f how well the viscoelastic is fulfilling its 
intended task. HPM C-preparations show little elastic­
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ity; therefore they are leaving the eye relatively quickly 
through the incision in cases o f elevated vitreous pres­
sure. Sodium hyaluronate products, in particularly those 
o f higher concentrations, can maintain anterior chamber 
depth due to their high elasticity.
A  further function is the mobilization and forcing 
back o f tissues in the anterior chamber. Examples o f this 
in cataract surgery are the gentle loosening o f synechiae 
between iris and lens, viscom ydriasis for pupillary dila­
tion, and filling the lens capsule prior to implantation.
V iscoelastics can perform  a protective function 
through the coating o f instruments, implants and tis­
sue surfaces (e.g. corneal endothelium). Prerequisites 
for this are low surface tension and a small water contact 
angle. HPM C-preparations as well as the combination 
preparation Viscoat® (Alcon) containing chondroitin 
sulfate and sodium  hyaluronate, possess significantly 
lower surface tension and water contact angles than pure 
sodium hyaluronate preparations, particularly those with 
high concentration and high molecular weight. Liquids 
spread more easily when their surface tension is lower 
than the critical surface tension o f the tissue [63]. The 
critical surface tension o f the corneal endothelium lies 
between 43 and 63 dynes/cm. The surface tension for 
HPM C-preparations should be at 4 3 ,0 11,4 1 dynes/cm, 
and at 62,716 ,51 dynes/cm for Healon [64]. Details con­
cerning the contact angle for various preparations are 
provided in table 3.1.1. For this, the contact angle was 
measured at 35° Celsius under nitrogen on PM M A [65]. 
Coating the corneal epithelial surface with viscoelastic, 
leads to a thorough, long-lasting moistening o f the cor­
nea with corresponding positive effects on the clarity 
o f the cornea. In addition, a drop o f viscoelastic can act 
like a m agnifying lens and therefore further improve 
the view in the anterior chamber. The protection o f the 
corneal endothelium represents an important function of 
a viscoelastic. In contrast to the corneal epithelium, the 
single-layered endothelium is not capable o f regenera­
tion following damage. Various factors can lead to the 
damage o f the endothelium during intraocular surgery. 
The endothelium can come in direct contact with lens 
fragments, instruments or the IOL. Furthermore the tur­
bulence o f the irrigation fluid can affect the endothelium. 
A ir bubbles, free radicals, and sound waves developed 
during phacoemulsification can also damage endothelial 
cells. The space-m aintaining function o f viscoelastics 
indirectly contributes to endothelial protection because 
the space for intraocular manipulation is maintained. 
Coating o f the endothelium, instruments and the IOL 
represent a further protective factor. Specific sodium  
hyaluronate binding areas were proven to be present 
at the endothelium [66-68]. It is assumed that sodium
hyaluronate containing products are able to offer a spe­
cial protective function because o f this. The continuous 
coating o f the endothelium, in particular offered by dis­
persive low-viscous substances, is generally seen as an 
important protective factor. A n overly extensive removal 
o f  the viscoelastic with the corresponding irrigation/ 
aspiration in the endothelial area may lead to endothelial 
damage, hence when using preparations such as Viscoat 
(Alcon), a thin layer can remain on the cornea.
Beside cataract surgery, viscoelastic devices are also 
used in other fields o f ophthalm ology, e.g. in kerato­
plasty- and glaucoma-, vitreoretinal-, and trauma sur­
gery. Because o f its extreme high ability to bind water 
relative to its mass this substance is therefore also used 
in numerous formulations o f eye drops used for dry eye 
symptoms [10, 33-37, 45, 46].
Complications using viscoelastic substances 
in ophthalmology
The use o f viscoelastics can also lead to intraoperative 
and postoperative complications. Intraocular structures 
can be damaged by overfilling the eye (zonular or cap­
sular rupture) or by incomplete removal at the end o f 
surgery (postoperative increase o f intraocular pressure). 
A n overfilling o f the eye depends more on the experience 
o f the surgeon than on the type o f viscoelastic. However, 
viscoelastics behave very individually during the remov­
al process. Viscoelastic that is left in the eye generally 
escapes as a large molecule by means o f the trabecular 
meshwork. The ability o f the viscoelastic to drain through 
this manner can be influenced by a variety o f factors.
Hyaluronic acid used as viscoelastic substance 
in other areas in medicine
Hyaluronic acid is an important structure-form ing m a­
trix in the human body, particularly in the joints. There 
hyaluronic acid is responsible for the strength (viscos­
ity) o f joint fluid (synovial fluid) and thus also crucial 
for the nutrition o f the cartilage. Like a film, hyaluronic 
acid covers the cartilage, smoothes and lubricates the 
surface. In osteoarthritic patients the synovial fluid 
shows a lower content o f hyaluronic acid as in healthy 
patients. By this viscosity and elasticity o f the synovial 
fluid is greatly altered. Hyaluronic acid injections replace 
or complement the mutated synovial fluid in osteoar­
thritis. These injections may stimulate the administra­
tion o f hyaluronic acid in the joints and the cells o f the 
synovium  to the increased production o f endogenous 
hyaluronic acid. Therefore hyaluronic acid is also widely 
used in human orthopedics as well as in veterinary medi­
cine. Hyaluronic acid reduces the symptoms o f most 
patients. A n improvement o f already existing alterations
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t a b . 1. Selection o f sodium hyaluronate based viscoelastics
PREPARATION POLYMER CONCENTRATION MANUFACTURER/DISTRIBUTOR
Healon Sodium hyaluronate 1.0% AMO
Healon 5 Sodium hyaluronate 2.3% AMO
Healon G V Sodium hyaluronate 1.4% AMO
Vitrax II Sodium hyaluronate 3.0% AMO
Amvisc Sodium hyaluronate 1.0% B&L
Amvisc Plus Sodium hyaluronate 1.6% B&L
Provisc Sodium hyaluronate 1.0% Alcon
Viscoat Sodium hyaluronate 
Chondroitinsulfate
3.0%
4 .0 %
Alcon
DuoVisc Sodium hyaluronate 
Chondroitinsulfate
(combination package o f Viscoat and Provisc)
See Viscoat and Provisc Alcon
DisCoVisc Sodium hyaluronate 
chondroitine sulfate
1.7%
4 .0 %
Alcon
Visthesia 1.0  and 1.5 sodium hyaluronate 
lidocaine (1.0) 
sodium hyaluronate 
lidocaine (1.5)
1.0%
1.0%
1.5%
1.0%
Zeiss
Rayvisc Sodium hyaluronate 3.0% Rayner
t a b . 2. Selection o f different HPM C products
PREPARATION POLYMER CONCENTRATION MANUFACTURER/DISTRIBUTOR
Adatocel H PM C 2.0% B&L
Coatel H PM C 2.0% B&L
HPMC-Ophtal H H PM C 2.0% Dr. Winzer
HPMC-Ophtal L H PM C 2.0% Dr. Winzer
La Gel H PM C 1.8% LA Labs
Ocucoat H PM C 2.0% B&L
Visco Shield 2% H PM C 2.0% Domilens
is not possible. Expected effects are pain reduction, im ­
provement o f quality o f life through increased mobility, 
reduced additional pain medication, and it delays the 
alteration progress [62].
Besides this, hyaluronic acid is also used as oral rins­
ing solution, gel or spray when dealing with oral mucosi­
tis [69]. Furthermore hyaluronic acid is also widely used 
in cosmetic skin preparations as moisturizer.
Mayor ophtalmo-movicosirgical products 
used in ophthalmology today
At present a multitude o f different viscoelastics are avail­
able on the market. Most products contain sodium hy- 
aluronate in different concentration followed by different 
H PM C preparations.
Viscoelastics can be classified according to their vis­
cosity, cohesiveness and dispersiveness; it can be distin­
guished between the following groups [1, 36]:
High viscous-cohesive viscoelastics:
— Molecular weight 5,000,000 to 7,900,000 Dalton,
— Zero shear viscosity: > 1000,000 mPs 
(Examples: Healon G V  (AMO), Healon 5 (AMO))
Viscous-cohesive viscoelastics:
— Molecular weight 100,000 to 6,100,000 Dalton,
— Zero shear viscosity: <1000,000 mPs> 100,000 mPs 
(Examples: Healon (AMO), Provisc (Alcon), 
A llervisc (Allergan), Am visc (Bauch + Lomb))
Middle viscous-dispersive viscoelastics:
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— Molecular weight 25,000 to 500,000 Dalton,
— Zero shear viscosity: <100,000 mPs> 10,000 mPs 
(Examples: Viscoat (Alcon), Cellugel (Alcon))
Low viscous-cohesive viscoelastics:
— Molecular weight 86,000 to 90,000 Dalton,
— Zero shear viscosity: < 10,000 mPs > 1,000 mPs 
(Examples: OcuCoat (Bauch + Lomb), Adatocel 
(Bausch + Lomb))
As far as the authors can evaluate, mayor ophthalmo- 
viscosurgical products on the European market are the fol­
lowing in regards o f their ingredient(s) (table 1 and 2).
Discussion
Development, production and use o f OVD require ongo­
ing research to evaluate the biocompatibility, purity, and 
ocular structure protection o f the materials in question 
[51-63]. In-vivo studies have proven that the molecular 
and chemical structure o f hyaluronic acid is ideal, and 
interactions between molecules, receptor tissues [64], 
inflammatory and immunogenic reactions [65] have also 
been studied extensively.
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